Logo

PreludeDx: Derek Maetzold

Feb 07, 2022

PreludeDx has appointed Derek Maetzold to its board of directors. Maetzold founded Castle Biosciences, serving as president, CEO, and a board member since its inception in 2007. He co-invented several Castle technologies and has contributed to the development and commercialization of five diagnostic and prognostic cancer tests.

Prior to Castle, Maetzold spent 24 years in pharma, holding leadership roles at Encysive Pharmaceuticals (acquired by Pfizer), Schering-Plough Corporation (now Merck), Integrated Communications (now FCB Health), Amylin Pharmaceuticals (now owned by AstraZeneca), and Sandoz Pharmaceuticals (now a division of Novartis).

Breaking News
The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.